» Advanced search
Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 1-1 of 1 results.
{{ selectedCountPage }} items selected on this page, {{ selectedCountPage }} item selected on this page, {{ selectedCountTotal }} item in total {{ selectedCountTotal }} items in total
Study aim: Comparative determination of the effect of two solutions of Chlorhexidine and sodium bicarbonate mouthwash on the onset of symptoms attributed to Covid-19 in vaccinated operating room staff of selected hospitals of Isfahan University of Medical Sciences in 2022 Design: A controlled clinical trial with parallel, double-blind, randomized groups on 120 patients. To divide the subjects into intervention and control groups, random allocation method and table of random numbers will be used. Settings and conduct: This study will be performed in selected hospitals of Isfahan. The intervention groups will receive Chlorhexidine mouthwash and sodium bicarbonate mouthwash and the control group receives placebo. Mouthwash and placebo will be used for two weeks, twice a day, 15 ml each time for one minute. From the start of mouthwash solutions until four weeks later, the studied samples will be monitored. To double-blind the study, participants will be unaware of the type of mouthwash solution and the data analyzer will be unaware of the details of the grouping. Participants/Inclusion and exclusion criteria: Get at least two doses of the vaccine, Personnel range of 18-60 years, Do not get Covid-19 in the last two months, No symptoms of systemic infection, Do not take immunosuppressive drugs, No history of allergy to mouthwash solutions, At least 2 weeks have passed since the second dose of the vaccine was given, No pregnancy, No breastfeeding Intervention groups: The intervention groups will receive chlorhexidine mouthwash and sodium bicarbonate mouthwash, and the control group received placebo (water). Mouthwash and placebo will use for two weeks, twice a day, 15 ml each time for one minute. From the start of mouthwash solutions until four weeks later, the samples will be monitored for symptoms. If necessary, PCR test will also be taken. Main outcome variables: Covid-19 symptoms, PCR test
IRCTID: IRCT20220328054364N1
  1. Evaluation of safety and immunogenicity of the SARS-CoV-2 recombinant spike RBD protein vaccine in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation; A phase 2 clinical trial
  2. Investigating the effectiveness of MMR vaccination The rate of COVID19 in medical staff compared to the control group
  3. Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial
  4. Comparison of effect of three mouthwashs, chlorhexidin, sodium bicarbonate and salin on bacterial colonization of endotracheal tubes and incidence of pneumonia in patients undergoing open heart surgery in Imam Ali Hospitat 2012-2013.
  5. Comparison of immune response to hepatitis B vaccine in simultaneous injections of Tetanus-diphtheria and B hepatitis vaccines with hepatitis B vaccine alone in Azahra staff having anti-HBs Ab lower than 100 IU/ml
  6. Evaluating the effectiveness of adding probiotic supplements to standard treatment in the treatment process of pregnant women with COVID-19: a double-blind randomized clinical trial
  7. Comparison the effect of sodium bicarbonate and zinc chloride mouth washes on incidence and severity of oral mucositis in patients with cancer under chemotherapy
  8. A double-blind, randomized, placebo-controlled Phase II clinical trial to evaluate the immunogenicity and safety of covid-19 recombinant RBD protein vaccine (80 microgram) of Plasma Darman Sarve Sepid Co. in healthy population.
  9. Evaluating the effect of Terminalia chebula, Pistacia lenticus and brown sugar oral preparation onrespiratory clinical findings and inflammatory indicators in patients with COVID-19
  10. Effect of Cinnamase drops on the incidence of clinical symptoms in asymptomatic individuals in the family of under treatment Covid 19 patients